Clinical Trials Browser

Phase 2 × Recurrence × Rituximab × Clear all

NCT03458260 2026-03-10

Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

Phase 2 Completed

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05283720 2026-03-03

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04268277 2026-02-27

Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

Phase 2 Terminated

22 enrolled 20 charts

Neoplasms, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT05498220 2025-09-02

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 2 Active not recruiting

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT07001540 2025-06-19

Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation

Phase 2 Recruiting

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03630042 2024-11-07

PembroWM

Phase 2 Completed

17 enrolled 7 charts

Waldenstrom Macroglobulinemia, Recurrence

NCT01199575 2024-08-15

Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Phase 2 Completed

30 enrolled 12 charts

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01134575 2024-07-16

CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)

Phase 2 Completed

90 enrolled 10 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05940051 2023-07-11

Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 2 Unknown

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04113226 2023-02-08

Relyage

Phase 2 Unknown

LymphoidSarcoma

Recurrence, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT03422523 2022-08-22

ARGO

Phase 2 Terminated

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04989621 2022-03-24

Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)

Phase 2 Unknown

Lymphoma, Follicular, Recurrence

NCT04994626 2021-08-06

Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

Phase 2 Unknown

Lymphoma, Recurrence

NCT01956695 2020-12-17

REVRI

Phase 2 Completed

Lymphoma, Recurrence

NCT02752204 2020-11-05

TORCH

Phase 2 Completed

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02481297 2020-05-28

Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients

Phase 2 Completed

7 enrolled 11 charts

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphoid, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00785330 2020-01-13

Allo-hNHL (FluBuCy)

Phase 2 Completed

Graft vs Host Disease, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral

NCT01576588 2019-12-27

Rituximab in Pretreated Elderly or Unfit B-CLL Patients

Phase 2 Completed

25 enrolled 9 charts

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02060656 2019-09-19

LEGEND

Phase 2 Unknown

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT00169208 2019-08-28

Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma

Phase 2 Completed

Lymphoma, Follicular, Recurrence

NCT02747732 2019-04-23

Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL

Phase 2 Unknown

Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT00201877 2018-03-12

Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma

Phase 2 Completed

25 enrolled 9 charts

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Mantle-Cell

NCT00867529 2018-01-02

Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma

Phase 2 Completed

63 enrolled 12 charts

LymphoidOther hematologic neoplasmSarcoma

Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Intraocular Lymphoma

NCT00617929 2017-12-28

Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant

Phase 2 Terminated

12 enrolled 12 charts

BreastCNSGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellSarcoma

Pdgfra-Associated Chronic Eosinophilic Leukemia, Carcinoma, Ovarian Epithelial, Breast Neoplasms, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Wilms Tumor, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Testicular Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile, Primary Myelofibrosis

NCT01466153 2017-05-31

A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Phase 2 Completed

183 enrolled 17 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01173679 2017-04-14

Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL

Phase 2 Terminated

10 enrolled 6 charts

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02420938 2016-12-06

Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients

Phase 2 Withdrawn

LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01007292 2015-10-19

A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment

Phase 2 Completed

Lymphoma, Non-Hodgkin, Recurrence

NCT00547534 2015-08-06

BVR

Phase 2 Completed

31 enrolled 9 charts

Lymphoma, Non-Hodgkin, Recurrence

NCT00968331 2012-08-27

Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Phase 2 Terminated

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT00071396 2012-08-07

Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders

Phase 2 Completed

48 enrolled 5 charts

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00509379 2011-01-28

LYM-2023

Phase 2 Completed

Lymphoma, Lymphoma, Non-Hodgkin, Recurrence

NCT00393107 2006-10-26

Safety and Efficacy of Fludarabine and Cyclophosphamide + Rituximab

Phase 2 Completed

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence

NCT00385125 2006-10-06

Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL

Phase 2 Unknown

Lymphoma, Non-Hodgkin, Recurrence

NCT00180895 2006-09-11

Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL

Phase 2 Terminated

Burkitt Lymphoma, Recurrence, Lymphoma, B-Cell